TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06616571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0605(PEG-rhG-CSF)
Description: Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QL0605(PEG-rhG-CSF)
Description: Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0605(PEG-rhG-CSF)
Description: Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QL0605(PEG-rhG-CSF)
Description: Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
Study: NCT06615791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT FIRST Teen
Description: High intensity sports drills and games.
Study: NCT06615895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth home activity
Description: Several course activities with diverse sensory modalities are provided a week. Caregivers or caretakers need to help children participate in the course content and implement relevant suggestions at least 3-5 times a week for six weeks. The research will be conducted on an online platform. Course announcements, reminders and confirmation of work execution, through caregivers\&#39; feedback records, urge caregivers to engage in parent-child games related to sensory integration and integrated into life at home. Such high-frequency, short-term sensory activities will be adapted to the equipment available at home. It will mainly focus on movement planning, bilateral integration/crossing the midline, vestibular system , visual perception, visual-motor integration, eye movements, core strength activities and Activities focused on balance ability.
Study: NCT06617442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: First pulmonary vein isolation performed for atrial fibrillation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: First pulmonary vein isolation performed for atrial fibrillation.
Study: NCT05039476

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Retinol face cream
Description: Retinol face cream

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo face cream
Description: Placebo face cream
Study: NCT06631729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV-bio
Description: participants will complete a HRV biofeedback task via the Elite HRV app. In this intervention, participants will learn how to use their HRV data that they will see in real-time via the Elite HRV app to improve their HRV by engaging in an app-guided diaphragmatic breathing exercise. They will complete this exercise twice daily (morning, night).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-JITAI
Description: participants will be prompted to complete focused, guided body scan tasks that will be sent to them via the MindLogger app. These guided tasks will be sent to them in the form of 1 of 3 brief (3-5 minute) videos via the MindLogger app. The body scans will be designed to promote participants' connection with, vs.~distancing/distraction from, feared ED sensations (e.g., hunger, satiety, bloating).~Participants will receive prompts to complete the body scans at times when they report via EMA that they are experiencing worse interoception than usual. Worse interoception than usual will be defined as participants' EMA-reported interoception scores during the intervention period that fall 1 SD or more above their baseline EMA-reported interoception levels.
Study: NCT03496883

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Activated Factor VII (rFVIIa)
Description: Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
Study: NCT06081686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I:[177Lu]Lu-XT033 Injection
Description: Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II:[177Lu]Lu-XT033 Injection
Description: Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
Study: NCT06393244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a theory-based home-based multi-component exercise training
Description: The participants in the intervention group will receive a 12-week theory-based home-based MCE program, which consists of three phases: exercise mobilization phase, exercise preparation phase (exercise instructions and exercise plan determination), and home-based autonomous exercise training. Structured guidelines have been developed for the intervention by the research team. This allowed interveners to deliver the intervention in a structured way with the same dosage.
Study: NCT06108271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triglotix®
Description: The Triglotix® has a biocompatible self-expanding viscoelastic cuff that is located in the supraglottic, glottic and subglottic space. This cuff separates the endotracheal tube from the laryngeal vestibule in the supraglottic space and the vocal cords avoiding direct tissue damage from the plastic components of the tube. The viscoelastic cuff self-expands after the endotracheal tube is in adequate position in the airway. Then it adapts progressively and gradually to the shape of structures it comes in contact with, applying minimal pressure to the surrounding tissue. The ETT-T also has two wire reinforced segments: the first is located outside the mouth to prevent deformation related with kinking, while the second segment is positioned distally along the larynx. The primary purpose of this design is to mitigate torsional, rotational and lateralization forces that the tube may encounter while the patient is intubated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional endotracheal tube
Description: Conventional endotracheal tube that is currently used worldwide
Study: NCT04367415

Intervention type: DIAGNOSTIC_TEST
Intervention: Darwish test for a free endometrial cavity
Description: Darwish test (Office hysteroscopic bubble suction and tubal peristalsis). If the uterine cavity is normal the patient will be allocated as group A

Intervention type: DIAGNOSTIC_TEST
Intervention: Darwish test for a free endometrial cavity
Description: Darwish test (Office hysteroscopic bubble suction and tubal peristalsis). If the uterine cavity is normal the patient will be allocated as group A

Intervention type: DIAGNOSTIC_TEST
Intervention: Darwish test for an endometrial cavity with endometrial polyps
Description: Darwish test (Office hysteroscopic bubble suction and tubal peristalsis).If there is one or more polyp(s) the patient will be allocated as group B.

Intervention type: DIAGNOSTIC_TEST
Intervention: Darwish test for an endometrial cavity with endometrial polyps
Description: Darwish test (Office hysteroscopic bubble suction and tubal peristalsis).If there is one or more polyp(s) the patient will be allocated as group B.
Study: NCT06358937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Assisted New Attachment Procedure using ND:YAG laser
Description: A free running, pulsed, 1064 nm wavelength-specific ND:YAG laser will be used. A thin 300 μm laser fiber optic will be placed parallel to the root surface, allows easy access into deep periodontal pockets. The initial pass with the laser is known as Laser Troughing, and it is done with a micro-short duration pulse, with a 4.0 watt power, 150 μs duration in pulsed mode and 20Hz frequency. Ultrasonic scaler will be then used to remove calculus. The second pass is carried out with 650 μs pulse duration, 10-30 seconds for each tooth, 4.0 watt power and 20HZ frequency, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed. Relieving the occlusion is the last step of the LANAP protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Assisted New Attachment Procedure using diode laser
Description: Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm attached with a power average set at 0.5-1.5 watt will be used.~The first pass laser troughing is done using a thin flexible fiber-optic cable 300 μm placed parallel to the root surface, attached with a power average set at 0.5-1 watt, in continuous mode. Ultrasonic scaler will be then used to remove calculus which present on the root surface. The second pass is carried out with 1-1.5 watt power in continuous mode, 10-30 seconds for each tooth, and, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed in order to enhance the healing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing using ultrasonic and curettes
Description: Scaling and root planing (SRP) using ultrasonic device at a moderate setting and with the appropriate tips and curettes will be also used where indicated and time spent in SRP on each tooth will not be restricted.
Study: NCT04760353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (OMNi-BiOTiC STRESS)
Description: OMNi-BiOTiC STRESS containing 9 human bacterial strains \[Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)\] and vitamin B (B2, B6, B12),

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~* Powder portion bags are suitable for participants with intolerance to yeasts or lactose~* Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks).
Study: NCT05116540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Autologous product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT05603039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: 200mg#D1#Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Study: NCT04385355

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional transmucosal abutment design
Description: The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow transmucosal abutment design
Description: The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
Study: NCT06178978

Intervention type: DEVICE
Intervention: KalEYEdoscope
Description: KalEYEdoscope is a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration. In the future, developing such a device for home monitoring of macular degeneration may increase access to timely treatment to prevent vision loss.~This study was conducted at the Kellogg Eye Center in Ann Arbor. Participants in the outpatient setting who agreed to enroll in the study tested the device and provided user feedback via a questionnaire as well as completed questionnaires about their visual function. This study assessed the usability, comfort, duration, ergonomics, and ease of use of the device among AMD patients in a single session.
Study: NCT04863794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
Study: NCT04836533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Computerized Cognitive Training
Description: Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Open-label antidepressant treatment
Description: Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Solitaire Training
Description: Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo-controlled antidepressant treatment
Description: Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.
Study: NCT05375188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
Study: NCT04957225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)
Description: Multimodal intensive treatment of aphasia and AOS
Study: NCT05706168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill exercise
Description: Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise
Description: Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
Study: NCT06549582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taohong Tongluo Xiaoban Prescription
Description: Chinese herbal medicine Taohong Tongluo Xiaoban prescription, which includes Pinelliae Rhizoma, Poria, Bambusae caulis in taenias, Aurantii Fructus Immaturus, Arisaema cum bile, Acori Tatarinowii Rhizoma, Persicae Semen, Carthami Flos, Chuanxiong Rhizoma and Paeoniae Radix Rubra as a once - daily dosage with one administration per dose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fundamental medical treatment
Description: The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fundamental medical treatment
Description: The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
Study: NCT05214924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin
Description: Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
Study: NCT05346601

Intervention type: DRUG
Group type: OTHER
Intervention: Chiauranib
Description: 50mg po only once

Intervention type: DRUG
Group type: OTHER
Intervention: Chiauranib
Description: 50mg po only once
Study: NCT04813016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal 1
Description: Early intraperitoneal injection of tramal and bupivacaine
Study: NCT05512624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion.
Study: NCT05618899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGH INTENSITY INTERVAL TRAINING
Description: Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
Study: NCT04927221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC371739 Tablets
Description: Participants received one of 5 dose levels of DC371739 administered as single oral doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered as comparison
Study: NCT05618899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MODERATE INTENSITY EXERCISE
Description: moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
Study: NCT04582591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 100 MG/ML
Description: Patients receive cannabidiol before and after treatment with chemotherapy
Study: NCT04744584

Intervention type: OTHER
Intervention: Medication reconciliation
Description: MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.

Intervention type: OTHER
Intervention: Medication reconciliation
Description: After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 12 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
Study: NCT05612230

Intervention type: OTHER
Intervention: Data analysis
Description: Data analysis is based on a single database from the National Health Medical Data (North Center).
Study: NCT03754322

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LAMP
Description: LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microscopy/RDT
Description: Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
Study: NCT06555614

Intervention type: OTHER
Intervention: Acellular Dermal Matrix(ADM)
Description: A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.

Intervention type: OTHER
Intervention: Acellular Dermal Matrix(ADM)
Description: A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.
Study: NCT05110040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunosuppressive agent
Description: patients with TAO recruited in this study will administrated with immunosuppressive agent per day
Study: NCT05291949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATLASense RAPHAEL PolyMonitor
Description: All patients will be monitored using the ATLASense RAPHAEL PolyMonitor during their surgery.